LA Private

October 16, 2024

Clarity Pharmaceuticals achieves milestones in prostate cancer trial

Clarity Pharmaceuticals (ASX:CU6) has reported significant developments in its SECuRE trial, which is evaluating the efficacy of 67Cu-SAR-bisPSMA for the treatment of prostate cancer. The third participant in cohort 4, a 93-year-old man with over 26 years of prostate cancer history, has completed the Dose Limiting Toxicity (DLT) period after receiving two doses of the

Clarity Pharmaceuticals achieves milestones in prostate cancer trial Read More »

Stocks of the Hour: Nyrada Inc, Errawarra Resources, Enlitic

To register for Friday’s webinar click here. Nyrada Inc (ASX:NYR) has successfully completed the final GLP safety study for its lead candidate, NYR-BI03. The company is now finalising its regulatory submission to the Human Ethics Research Committee (HREC), a key step toward starting its first-in-human Phase I clinical trial, expected to begin in Q4 2024.

Stocks of the Hour: Nyrada Inc, Errawarra Resources, Enlitic Read More »

ASX down 0.3% near noon: Financials the only sector in the green

Australian shares fell, following losses on Wall Street, driven by reduced demand for natural resource-related assets. At 11:55am, the S&P/ASX 200 is 0.3 per cent lower at 8,293.30. The SPI futures are pointing to a fall of 26 points. Best and worst performers The best-performing sector is Financials, up 0.27 per cent. The worst-performing sector

ASX down 0.3% near noon: Financials the only sector in the green Read More »

Monadelphous secures $160m in new contracts and extensions

Engineering services company Monadelphous Group (ASX:MND) has announced a series of new contracts and extensions valued at approximately $160 million. These deals span several key mining and industrial sectors across Western Australia. Among the awards, Monadelphous secured a pair of one-year contract extensions with Rio Tinto (ASX:RIO) for fixed plant maintenance and capital projects at

Monadelphous secures $160m in new contracts and extensions Read More »

Challenge accepted

Challenger Limited (ASX:CGF) posted strong first-quarter results for FY25, with total assets under management increasing to $128 billion, up 1%. Total Life sales reached $2.4 billion, driven by a 26% rise in retail lifetime annuity sales and a significant 74% increase in Japanese annuities. However, fixed-term annuity sales saw a drop of 28% due to

Challenge accepted Read More »

Bank of Queensland reports strong profit, but lending challenges persist

Bank of Queensland (ASX:BOQ) has announced its FY24 results, reporting a significant rise in statutory net profit after tax to $285 million, a 130% increase from FY23. However, cash earnings after tax saw a 24% decline to $343 million, reflecting challenges in a competitive lending market and rising operational costs. BOQ’s net interest margin decreased

Bank of Queensland reports strong profit, but lending challenges persist Read More »